71 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
, subject to community property laws, where applicable. Except as otherwise noted below, the street address of each beneficial owner is c/o Larimar
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
upcoming pivotal milestones designed to help address the urgent unmet needs of the FA community.”
Recent Highlights
In February 2024, Larimar announced
8-K
EX-99.1
94s2 pfd2k9
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
exl2vvuf wm
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
EX-99.1
a5txxjm
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
5lsyt
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
h9hxsjg7ie 1tlur7
11 May 21
Other Events
8:34am